You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD1

Showing 576 - 600 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumors Trial in Nedlands (YH003, Toripalimab, Nab-paclitaxel)

Active, not recruiting
  • Advanced Solid Tumors
  • Nedlands, Western Australia, Australia
    Linear Clinical Research
Dec 29, 2021

Non-cutaneous Squamous Cell Carcinoma of Head and Neck Trial in United States (ALKS 4230, Pembrolizumab)

Completed
  • Non-cutaneous Squamous Cell Carcinoma of Head and Neck
  • Miami, Florida
  • +5 more
Nov 10, 2022

Unresectable Melanoma Trial in Pittsburgh (Nivolumab, Duvelisib)

Recruiting
  • Unresectable Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Apr 19, 2022

PD-1 Antibody, Mixed Chimerism Trial in Beijing (Toripalimab Injection)

Not yet recruiting
  • PD-1 Antibody
  • Mixed Chimerism
  • Toripalimab Injection
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Jun 27, 2021

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

Urothelial Carcinoma Trial in Mainz (Cabozantinib)

Terminated
  • Urothelial Carcinoma
  • Mainz, Germany
    Department of Urology of the University Medical Center Mainz
Aug 24, 2021

Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Oct 14, 2022

Solid Advanced Tumor, Lymphoma Trial in Belgium, France (OSE-279 100mg, OSE-279 300mg, OSE-279 500mg)

Recruiting
  • Solid Advanced Tumor
  • Lymphoma
  • OSE-279 100mg
  • +2 more
  • Anderlecht, Belgium
  • +5 more
Feb 27, 2023

Glioblastoma Trial in Zhengzhou (Tislelizumab plus Bevacizumab)

Recruiting
  • Glioblastoma
  • Tislelizumab plus Bevacizumab
  • Zhengzhou, Henan, China
    Henan Provincial People's Hospital
Aug 14, 2022

Advanced Lung Cancer Trial (6MW3211)

Not yet recruiting
  • Advanced Lung Cancer
  • (no location specified)
Jun 20, 2022

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma Trial (BGB-A445, Tislelizumab)

Not yet recruiting
  • Urothelial Carcinoma
  • +2 more
  • (no location specified)
Dec 15, 2022

Advanced NSCLC Trial in Nanjing (AK104, Docetaxel)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Mar 24, 2022

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone

Completed
  • Hepatocellular Carcinoma
  • TACE-HAIC
  • +3 more
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 8, 2022

Gastric Cancer Trial in Jinan (SHR1210, Apatinib, S1)

Recruiting
  • Gastric Cancer
  • Jinan, Shandong, China
    Qilu hospital of Shandong univertisy
Mar 30, 2022

Gastric Adenocarcinoma, Esophageal Adenocarcinoma Trial in Netherlands (Capecitabine, Oxaliplatin, Retifanlimab)

Recruiting
  • Gastric Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Amsterdam, Netherlands
  • +7 more
Jan 31, 2022

Metastatic Non Small Cell Lung Cancer Trial in Singapore (Nivolumab, ADG106)

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Singapore, Singapore
  • +1 more
Mar 10, 2022

Liver Cancer Trial in Guanzhou (PD1/PDL1 inhibitor)

Unknown status
  • Liver Cancer
  • PD1/PDL1 inhibitor
  • Guanzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Apr 4, 2021

Cervical Cancer Trial in Beijing (HLX10+Albumin-Bound Paclitaxel)

Active, not recruiting
  • Cervical Cancer
  • HLX10+Albumin-Bound Paclitaxel
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
May 4, 2022

Importance of PD-1/PD-L1 and IL-10/IL-10R Axis in Malignant and

Recruiting
  • Pleural Effusion
  • Pleural effusion will be examined for various cytokines and PD1-lymphocytes.
  • Vienna, Austria
    Medical University of Vienna
Apr 4, 2021

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Follicular Lymphoma Trial in Saint Louis (biological, drug, procedure)

Suspended
  • Follicular Lymphoma
  • Personalized tumor vaccine
  • +6 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 9, 2021

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)

Not yet recruiting
  • Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
  • SG001 injection
  • +5 more
  • (no location specified)
Jan 27, 2023

Mycosis Fungoides Trial in Edmonton (Cemiplimab)

Not yet recruiting
  • Mycosis Fungoides
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Sep 12, 2022

Nasopharyngeal Carcinoma Trial in Beijing, Shanghai (AK105)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • AK105
  • Beijing, Beijing, China
  • +1 more
Mar 30, 2022